« Six Sigma in Drug Discovery? Part One - Are Chemists Too Individual? |
Main
| The Life of a Key Opinion Leader »
September 16, 2010
Live-Blogging Arena's FDA Committee Hearing
Posted by Derek
San Diego newspaper blogger Keith Darce is doing it here. The meeting should start up again about 1 PM Eastern. So far, the company and the FDA staff have been presenting reviews of the Lorcaserin data. The committee member questions don't look particularly encouraging. . .
Update: the committee votes "No", 9-5. We'll see what the agency itself does. I expect the same outcome.
Comments (7)
+ TrackBacks (0) | Category: Diabetes and Obesity | Regulatory Affairs
POST A COMMENT
- RELATED ENTRIES
- › Academia and Industry, Suing Each Other
- › Let's Start Off the Meeting With An Ad, OK?
- › The Academic-Industrial Collaboration in Drug Discovery Panel: Today
- › Glass Structure, Atom by Atom
- › How the Andrulis Paper Got Published
- › AstraZeneca in Waltham
- › Fluorine NMR: Why Not?
- › AstraZeneca Layoffs and Closings
1. In Vivo Veritas on September 16, 2010 12:42 PM writes...
Better coverage here:
Permalink to Commenthttp://www.coveritlive.com/index2.php/option=com_altcaster/task=viewaltcast/altcast_code=c7a8716060/height=550/width=600
2. anchor on September 16, 2010 1:10 PM writes...
Permalink to Comment..this is almost like watching Gore V Bush!
3. HappyDog on September 16, 2010 2:04 PM writes...
Regarding the FDA staffer's comment about the patient that attempted suicide while on Lorcaserin, does this mean that embezzlement will have to appear on the label as a possible side effect if the drug is approved?
Permalink to Comment4. In Vivo Veritas on September 16, 2010 2:04 PM writes...
You called it Lowe - voted down.
Permalink to Comment5. glinkst on September 17, 2010 9:19 AM writes...
So what is the lowedown? No chance for approval? The response for orexigen is interesting. Market is saying arena's problems are arena's and not obesity as an indication.
Permalink to CommentAs a pure guess only, it suggests that the animal tumor data may have weighed more than some of the other side effects. The lowest dose administered in rats showed an effect, which is not good. The other side effects seemed managable IMUHO.
G
6. not a chemist on September 20, 2010 2:10 PM writes...
IMHO, any anti-obesity drug that has psychiatric side effects has a snowball's chance in hell as far as FDA approval goes. How someone came up with such a dim idea as topiramate + amphetamine analog and thought they'd have a winner, I'll never know. (Disclaimer: I have used topiramate for psychiatric indications. It isn't the best in class for the particular indication I was taking it, but it is - unlike most other psychiatric drugs - a great weight loss aid, and definitely not a drug to be taken lightly.)
Permalink to Comment7. Evorich on September 20, 2010 5:02 PM writes...
In the end it's risk vs. reward, and for something to have such a small reward and have any risk - it just ends up being not worth approving.
Permalink to Comment